この資料は、モデルナ（マサチューセッツ州ケンブリッジ）が2025年6月30日（現地時間）に発表したものを日本語に翻訳したもので、報道関係者の皆さまに参考資料として提供するものです。資料の内容および解釈については、英語が優先されます。英語版は、 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

Moderna (NASDAQ:MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...